Background: Proton pump inhibitors (PPIs) are widely used over-the-counter drugs for treatment of acid peptic disease. Irrational use of PPIs without proper indication has exposed patients to unnecessary risks. Currently, PPIs are under scrutiny by U.S.FDA to determine risk of community acquired pneumonia (CAP) as conflicting results have been obtained from various studies. Aim: The aim of our study was to evaluate the risk of CAP with use of PPIs in adults. Methods: We searched PUBMED and MEDLINE databases to identify studies meeting the inclusion criteria. All titles and abstracts were screened independently and in duplicate by authors for eligibility. The primary outcome was first episode of CAP. Only observational studies with a comparison arm were included. Results : Based on eligibility criteria, five observational studies were included for analysis. Conclusion: Further randomised controlled trials are needed to clarify the risk of CAP with PPI therapy .